Among the combination therapies, concurrent anti-Tie2 showed the greatest potential for inhibiting tumor invasiveness compared to paclitaxel alone – histology revealed a decrease from 50% to 20% (Fig. 3A). This evidence concerns the gene TEK and neoplasm.